Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an update.
Australian Clinical Labs Ltd announced the cessation of 750,000 ordinary fully paid securities due to an on-market buy-back, effective May 19, 2025. This move is part of the company’s capital management strategy, potentially impacting its share value and signaling a focus on optimizing shareholder returns.
The most recent analyst rating on (AU:ACL) stock is a Buy with a A$4.25 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily focusing on providing pathology services. The company is a key player in the Australian market, offering a range of diagnostic services to healthcare professionals and patients.
Average Trading Volume: 1,033,756
Technical Sentiment Signal: Sell
Current Market Cap: A$610.9M
For an in-depth examination of ACL stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue